Compare Amgen, Inc. (AMGN) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Atlassian Corporation PLC — how do they compare? Amgen, Inc. trades at $356.83 (market cap $196.12B), while Atlassian Corporation PLC trades at $94.48 (market cap $22.55B). The key difference: Amgen, Inc. is far larger — about 8.7× Atlassian Corporation PLC's market cap, and Amgen, Inc. pays a 2.77% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| AMGN | TEAM | |
|---|---|---|
Market Cap | $196.12B | $22.55B |
Sector | Health | Technology |
52-Week High | $388.16 | $203.00 |
52-Week Low | $271.18 | $57.15 |
Enterprise Value | $241.41B | $22.66B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Atlassian (TEAM) trades at $88.86, down 2.04% today, with strong technical momentum indicated by bullish moving averages. The company shows accelerating revenue growth reaching $5.22B in 2025, though it remains unprofitable with a -3.5% net margin. Recent earnings beats and cloud revenue growth of 29% in Q3 FY26 demonstrate business momentum, while analyst consensus remains strongly bullish with a $119.93 price target representing 35% upside potential.
TEAM presents a compelling growth story with improving fundamentals and strong analyst support, though profitability challenges and AI disruption risks require monitoring. The stock's current valuation at 3.77x sales appears reasonable given the 30%+ revenue growth trajectory, making it attractive for growth-oriented investors willing to accept near-term losses for long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
